{"protocolSection": {"identificationModule": {"nctId": "NCT00264849", "orgStudyIdInfo": {"id": "CIGE025A2425"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma", "officialTitle": "A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy"}, "statusModule": {"statusVerifiedDate": "2018-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-11"}, "primaryCompletionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-12-12", "studyFirstSubmitQcDate": "2005-12-12", "studyFirstPostDateStruct": {"date": "2005-12-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-03", "resultsFirstSubmitQcDate": "2011-06-24", "resultsFirstPostDateStruct": {"date": "2011-07-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-04-17", "lastUpdatePostDateStruct": {"date": "2018-06-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}, "collaborators": [{"name": "Genentech, Inc.", "class": "INDUSTRY"}, {"name": "Tanox", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control. Response to omalizumab over time will be assessed by physicians and patients evaluating the overall improvement in control of their asthma.\n\nTHIS STUDY IS NOT ENROLLING PATIENTS IN THE US."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "omalizumab", "Severe persistent allergic asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 406, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "OAT + Omalizumab", "type": "EXPERIMENTAL", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level.", "interventionNames": ["Drug: Omalizumab", "Other: Optimized asthma therapy"]}, {"label": "Optimized Asthma Treatment (OAT)", "type": "ACTIVE_COMPARATOR", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for 32 weeks.", "interventionNames": ["Other: Optimized asthma therapy"]}], "interventions": [{"type": "DRUG", "name": "Omalizumab", "description": "Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.", "armGroupLabels": ["OAT + Omalizumab"], "otherNames": ["Xolair"]}, {"type": "OTHER", "name": "Optimized asthma therapy", "description": "Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.", "armGroupLabels": ["OAT + Omalizumab", "Optimized Asthma Treatment (OAT)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE)", "description": "Persistency of response, based on GETE, was dichotomized into responders (excellent or good) and non-responders (moderate, poor or worsening). Persistent responders were patients who were responders at 16 weeks and still at 32 weeks. Persistent non-responders were patients who were non-responders at 16 weeks and still at 32 weeks. Patients were assessed for persistency of response if they were responders at Week 16 and had a second GETE obtained \u2265 4 weeks after the Week 16 assessment or discontinued prematurely for unsatisfactory therapeutic effect \u2265 4 weeks after the Week 16 assessment.", "timeFrame": "Weeks 16 and 32"}], "secondaryOutcomes": [{"measure": "Number of Participants by Investigator's Global Evaluation of Treatment Effectiveness (GETE) Category at Week 16 and Week 32", "description": "Number of participants with persistent response, based on the investigator's GETE, dichotomized to responders (excellent or good) and non-responders (moderate, poor or worsening) for patients receiving omalizumab as add on to optimal asthma therapy, assessed at week 16 and week 32. Persistency was defined as the proportion of responders at 16 weeks who were still responders at 32 weeks. GETE categories are excellent, good, moderate, poor, worsening, and missing as determined by the investigator.", "timeFrame": "Weeks 16 and 32"}, {"measure": "Percentage of Participants Who Were Responders at Both Week 16 and Week 32 Based on Investigator's GETE", "description": "Responders were defined as excellent or good based on the investigator's Global Evaluation of Treatment Effectiveness (GETE) for patients receiving omalizumab as add on to optimal asthma therapy, assessed at week 16 and week 32.", "timeFrame": "Weeks 16 and 32"}, {"measure": "Number of Participants by Patient's Global Evaluation of Treatment Effectiveness (GETE) Category at Week 16 and 32", "description": "Number of participants with persistent response, based on the patient's GETE, dichotomized to responders (excellent or good) and non-responders (moderate, poor or worsening) for patients receiving omalizumab as add on to optimal asthma therapy, assessed at week 16 and week 32. Persistency was defined as the proportion of responders at 16 weeks who were still responders at 32 weeks. This is based on the patient's evaluation.", "timeFrame": "Weeks 16 and 32"}, {"measure": "Percentage of Participants Who Were Responders at Both Week 16 and Week 32 Based on Patient's GETE", "description": "Responders were defined as excellent or good based on the patient's Global Evaluation of Treatment Effectiveness (GETE) for patients receiving omalizumab as add on to optimal asthma therapy, assessed at week 16 and week 32.", "timeFrame": "Weeks 16 and 32"}, {"measure": "Lung Function Assessed by Forced Expiratory Volume for 1 Second (FEV1)", "description": "Predicted FEV1 was calculated using the Crapo formula for data at Visit 6 (time of randomization), (MALES: Predicted FEV1 (L) = 0.0414\\*height - 0.0244\\*age -2.190 and Females: Predicted FEV1 (L) = 0.0342\\*height - 0.0255\\*age - 1.578, where height is in cm).", "timeFrame": "Weeks 16 and 32"}, {"measure": "Change From Baseline in Asthma Control Questionnaire (ACQ) Overall Score at Weeks 16 and 32", "description": "Asthma symptoms were evaluated by the Asthma Control Questionnaire (ACQ). The ACQ has six questions to be answered by the patient, each with a 7 point scale (0-good control, 6-poor control), and one question where the actual pre-bronchodilator FEV1 value expressed in % of predicted FEV1 was classified to scores from 0 (\\> 95% of predicted) to 6 (\\< 50% of predicted). The overall score is the average of the 7 questions; a minimum overall score of 0 = good control of asthma whereas a maximum overall score of 6 = poor control of asthma. A negative change in score indicates improvement in symptoms.", "timeFrame": "Baseline, Week 16, Week 32"}, {"measure": "Number Participants With Clinically Significant Asthma Exacerbations by Category During the 32 Week Treatment Period", "description": "A clinically significant exacerbation episode was defined as a worsening of asthma requiring treatment with rescue systemic (oral or IV) corticosteroids. The initiation of the rescue systemic corticosteroids marked the start of a clinically significant asthma exacerbation episode and cessation of the rescue systemic corticosteroids regimen marked the end of a clinically significant exacerbation episode. If an exacerbation episode was duplicated, overlapped by at least one day with another episode, or nested within another exacerbation episode, only one exacerbation was counted.", "timeFrame": "32 Weeks"}, {"measure": "Medical Resource Utilization: Number of Participants With Combined Hospital Admissions, Emergency Room Visits, and Other Outpatient Clinical Visits Due to an Asthma Exacerbation During the 32 Week Treatment Period", "description": "A combined total of unscheduled visits due to asthma exacerbations was calculated for each patient as the total number of hospital admissions, ER visits and unscheduled outpatient clinical visits due to asthma exacerbation. Where more than one type of visit was required on a single day for an asthma exacerbation only the most serious type was included. Where there was more than one visit for a single asthma exacerbation but the visits occurred on different dates, then all were counted.", "timeFrame": "32 Weeks"}, {"measure": "Percent Change in Dose of Maintenance Systemic Steroids at Weeks 16 and 32", "description": "For the subgroup of patients requiring maintenance oral (systemic) corticosteroids throughout the screening period the dose of oral steroid (expressed as prednisolone equivalent dose) at baseline, Week 16 and Week 32 was presented by treatment group, as well as the absolute and percent change from baseline to Weeks 16 and 32. It should be noted that the dose of oral steroid at Weeks 16 and 32 was the dose the patient was maintained on and not the dose to treat an exacerbation if one occurred at that time.", "timeFrame": "Weeks 16 and 32"}, {"measure": "Number of Participants by Type of Dose Change of Maintenance Systemic Steroids at Weeks 16 and 32", "description": "The type of change for the dose of maintenance systemic steroids could be presented as removal (no more maintenance systemic steroids used), decreased, or maintained.", "timeFrame": "Weeks 16 and 32"}, {"measure": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Overall Score by Visit", "description": "There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental exposure). Each question was answered on a 7 point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). The overall AQLQ score is the mean of all 32 responses, and the individual domain scores are the means of the items in those domains (a minimum domain / overall score of 1 = Severely impaired whereas a maximum domain / overall score of 7 = not impaired at all). A positive change from baseline score indicates improvement.", "timeFrame": "Baseline, Week 15, Week 31"}, {"measure": "Change From Baseline in EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) Index Score and Health State Assessment on Scale From 0 to 100 at Weeks 15 and 31", "description": "The utility-based EQ-5D questionnaire is in two parts and provides a generic measure of health for clinical and economic appraisal. The first \"health state classification\" part has 5 questions each with 3 categories (no problem, moderate problem, severe problems). The second \"visual analogue scale\" was measured from 0 (worst imaginable health state) to 100 (best imaginable health state).", "timeFrame": "Baseline, Week 15, Week 31"}, {"measure": "Changes From Baseline to Week 31 in the Percent Overall Work Impairment Due to Asthma Problems", "description": "The Work Productivity and Activity Impairment-Allergic Asthma (WPAI-AA) questionnaire measures time missed from work, impairment of work and regular activities within the last 7 days. Questionnaires were administered via phone 1 week prior to the study visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Overall work impairment due to asthma problems is derived from the proportion of hours missed from work due to asthma and the degree to which asthma problems affected productivity while working.", "timeFrame": "Baseline and Week 31"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nPatients who met the following criteria were included:\n\n* Males or females of any race, who were 12-75 years of age\n* A body weight \u2265 20 kg and \u2264 150 kg and with a total serum IgE level \u2265 30 to \u2264 700 IU/ml\n* A diagnosis of allergic asthma \u2265 1 year duration according to American Thoracic Society (ATS) criteria and at screening a history consistent with GINA (2204) step 3 or 4 clinical features\n* A positive prick skin test (diameter of wheal \\>= 3 mm) to at least one perennial allergen documented within the past 2 years or taken at visit 1\n* Increase in FEV1 \u226512% over baseline value within 30 minutes of taking 2 to 4 puffs (2-4x100\u00b5g) salbutamol (albuterol) or nebulized salbutamol up to 5mg\n* An FEV1 \u2265 40 and \u2264 80% of the predicted normal value for the patient at randomization\n* Receiving moderate to high dose inhaled corticosteroid \u2265 800 \u00b5g BDP or equivalent and a regular inhaled long acting B-2 agonists for at least 3 months prior to screening and \\> 1000 \u00b5g (BDP) and a LABA for at least 4 weeks during the run-in and at randomization\n* Patients who have suffered multiple (i.e. at least two) independent documented severe asthma exacerbations while receiving high doses of ICS (\u2265 800 \u00b5g BDP or equivalent) plus regular inhaled LABA\n* Evidence of poor asthma control at screening (based on patient history) and for at least 4 weeks immediately prior to randomisation\n\nExclusion Criteria:\n\nPatients who met the following criteria were excluded:\n\n* Had received systemic corticosteroids for reasons other than asthma within 4 weeks of Visit 1\n* A smoking history \\>10 pack years\n* An active lung disease other than allergic asthma\n* Elevated serum IgE levels for reasons other than allergy\n* Patients with significant underlying medical conditions", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_CHAIR"}], "locations": [{"city": "Bruxelles", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"city": "Montreal", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"city": "Hvidovre", "country": "Denmark", "geoPoint": {"lat": 55.65719, "lon": 12.47364}}, {"city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Athens", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"city": "Dublin", "country": "Ireland", "geoPoint": {"lat": 53.33306, "lon": -6.24889}}, {"city": "Haifa", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"city": "Roma", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"city": "Oslo", "country": "Norway", "geoPoint": {"lat": 59.91273, "lon": 10.74609}}, {"city": "Lodz", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"city": "Lisboa", "country": "Portugal", "geoPoint": {"lat": 38.71667, "lon": -9.13333}}, {"city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"city": "Stockholm", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"city": "Bern", "country": "Switzerland", "geoPoint": {"lat": 46.94809, "lon": 7.44744}}, {"city": "Bursa", "country": "Turkey", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}, {"city": "Nottingham", "country": "United Kingdom", "geoPoint": {"lat": 52.9536, "lon": -1.15047}}]}, "referencesModule": {"references": [{"pmid": "21933100", "type": "DERIVED", "citation": "Siergiejko Z, Swiebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011 Nov;27(11):2223-8. doi: 10.1185/03007995.2011.620950. Epub 2011 Sep 21."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "FG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "275"}, {"groupId": "FG001", "numSubjects": "131"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "253"}, {"groupId": "FG001", "numSubjects": "106"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "25"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Administrative Problems", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "BG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "272"}, {"groupId": "BG001", "value": "128"}, {"groupId": "BG002", "value": "400"}]}], "measures": [{"title": "Age, Categorical", "description": "All demographic data is described for the Modified ITT population. The modified ITT population includes all randomized patients with at least one post-baseline efficacy assessment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "250"}, {"groupId": "BG001", "value": "118"}, {"groupId": "BG002", "value": "368"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "27"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.6", "spread": "13.04"}, {"groupId": "BG001", "value": "45.7", "spread": "12.57"}, {"groupId": "BG002", "value": "45.7", "spread": "12.87"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "183"}, {"groupId": "BG001", "value": "76"}, {"groupId": "BG002", "value": "259"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "89"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "141"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "266"}, {"groupId": "BG001", "value": "125"}, {"groupId": "BG002", "value": "391"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE)", "description": "Persistency of response, based on GETE, was dichotomized into responders (excellent or good) and non-responders (moderate, poor or worsening). Persistent responders were patients who were responders at 16 weeks and still at 32 weeks. Persistent non-responders were patients who were non-responders at 16 weeks and still at 32 weeks. Patients were assessed for persistency of response if they were responders at Week 16 and had a second GETE obtained \u2265 4 weeks after the Week 16 assessment or discontinued prematurely for unsatisfactory therapeutic effect \u2265 4 weeks after the Week 16 assessment.", "populationDescription": "Modified Intent-to-Treat (mITT) was defined for efficacy analyses which included all randomized patients who had at least one post-baseline efficacy assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Weeks 16 and 32", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "Number of responders at Wk 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "29"}]}]}, {"title": "Participants available to assess persistency", "categories": [{"measurements": [{"groupId": "OG000", "value": "187"}, {"groupId": "OG001", "value": "28"}]}]}, {"title": "Number of Persistent Responders at Weeks 16 and 32", "categories": [{"measurements": [{"groupId": "OG000", "value": "171"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Number of non-responders at Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "64"}]}]}, {"title": "Participants to assess persistency of non respond", "categories": [{"measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "63"}]}]}, {"title": "Number of Persistent Non-responders at Wks 16and32", "categories": [{"measurements": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "57"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants by Investigator's Global Evaluation of Treatment Effectiveness (GETE) Category at Week 16 and Week 32", "description": "Number of participants with persistent response, based on the investigator's GETE, dichotomized to responders (excellent or good) and non-responders (moderate, poor or worsening) for patients receiving omalizumab as add on to optimal asthma therapy, assessed at week 16 and week 32. Persistency was defined as the proportion of responders at 16 weeks who were still responders at 32 weeks. GETE categories are excellent, good, moderate, poor, worsening, and missing as determined by the investigator.", "populationDescription": "Modified Intent-to-Treat (mITT)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Weeks 16 and 32", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "Week 16: Excellent", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Week 16: Good", "categories": [{"measurements": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "28"}]}]}, {"title": "Week 16: Moderate", "categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "24"}]}]}, {"title": "Week 16: Poor", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "34"}]}]}, {"title": "Week 16: Worsening", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Week 16: Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "35"}]}]}, {"title": "Week 16: Responders (excellent and good)", "categories": [{"measurements": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "29"}]}]}, {"title": "Week 16: Non-responders (moderate, poor, worse)", "categories": [{"measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "64"}]}]}, {"title": "Week 32: Excellent", "categories": [{"measurements": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Week 32: Good", "categories": [{"measurements": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "24"}]}]}, {"title": "Week 32: Moderate", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "31"}]}]}, {"title": "Week 32: Poor", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "39"}]}]}, {"title": "Week 32: Worsening", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Week 32: Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "24"}]}]}, {"title": "Week 32: Responders (excellent and good)", "categories": [{"measurements": [{"groupId": "OG000", "value": "199"}, {"groupId": "OG001", "value": "25"}]}]}, {"title": "Week 32: Non-responders (moderate, poor, worse)", "categories": [{"measurements": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "79"}]}]}, {"title": "Responder at both weeks (Weeks 16 and 32)", "categories": [{"measurements": [{"groupId": "OG000", "value": "171"}, {"groupId": "OG001", "value": "18"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Were Responders at Both Week 16 and Week 32 Based on Investigator's GETE", "description": "Responders were defined as excellent or good based on the investigator's Global Evaluation of Treatment Effectiveness (GETE) for patients receiving omalizumab as add on to optimal asthma therapy, assessed at week 16 and week 32.", "populationDescription": "Modified Intent-to-Treat (mITT)", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 16 and 32", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "62.9", "lowerLimit": "57.1", "upperLimit": "68.6"}, {"groupId": "OG001", "value": "14.1", "lowerLimit": "8.0", "upperLimit": "20.1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants by Patient's Global Evaluation of Treatment Effectiveness (GETE) Category at Week 16 and 32", "description": "Number of participants with persistent response, based on the patient's GETE, dichotomized to responders (excellent or good) and non-responders (moderate, poor or worsening) for patients receiving omalizumab as add on to optimal asthma therapy, assessed at week 16 and week 32. Persistency was defined as the proportion of responders at 16 weeks who were still responders at 32 weeks. This is based on the patient's evaluation.", "populationDescription": "Modified Intent-to-Treat (mITT)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Weeks 16 and 32", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "Week 16: Excellent", "categories": [{"measurements": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Week 16: Good", "categories": [{"measurements": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "29"}]}]}, {"title": "Week 16: Moderate", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "23"}]}]}, {"title": "Week 16: Poor", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "33"}]}]}, {"title": "Week 16: Worsening", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Week 16: Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "34"}]}]}, {"title": "Week 16: Responders (excellent and good)", "categories": [{"measurements": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "33"}]}]}, {"title": "Week 16:Non-responders (moderate, poor, worsening)", "categories": [{"measurements": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "61"}]}]}, {"title": "Week 32: Excellent", "categories": [{"measurements": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Week 32: Good", "categories": [{"measurements": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "27"}]}]}, {"title": "Week 32: Moderate", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "28"}]}]}, {"title": "Week 32: Poor", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "38"}]}]}, {"title": "Week 32: Worsening", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Week 32: Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "25"}]}]}, {"title": "Week 32: Responders (excellent and good)", "categories": [{"measurements": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "29"}]}]}, {"title": "Week 32: Non-responders (moderate, poor, worse)", "categories": [{"measurements": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "74"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Were Responders at Both Week 16 and Week 32 Based on Patient's GETE", "description": "Responders were defined as excellent or good based on the patient's Global Evaluation of Treatment Effectiveness (GETE) for patients receiving omalizumab as add on to optimal asthma therapy, assessed at week 16 and week 32.", "populationDescription": "mITT population and patients who were assessed for persistency of response or non-response at Week 16 and had a GETE obtained \\>= 4 weeks after the Week 16 assessment or discontinued prematurely or unsatisfactory therapeutic effect \\>= 4 weeks after the Week 16 assessment. N=187/28 for OAT+Omalizumab/OAT for responders and N=71/63 for non-responders.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 16 and 32", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "63.2", "lowerLimit": "57.5", "upperLimit": "69.0"}, {"groupId": "OG001", "value": "15.6", "lowerLimit": "9.3", "upperLimit": "21.9"}]}]}]}, {"type": "SECONDARY", "title": "Lung Function Assessed by Forced Expiratory Volume for 1 Second (FEV1)", "description": "Predicted FEV1 was calculated using the Crapo formula for data at Visit 6 (time of randomization), (MALES: Predicted FEV1 (L) = 0.0414\\*height - 0.0244\\*age -2.190 and Females: Predicted FEV1 (L) = 0.0342\\*height - 0.0255\\*age - 1.578, where height is in cm).", "populationDescription": "Modified Intent-to-Treat (mITT), for Week 16 N=258/106 for OAT+Omalizumab/OAT and for Week 32 N=266/121 for OAT+Omalizumab/OAT, respectively.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent predicted FEV1", "timeFrame": "Weeks 16 and 32", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "68.4", "lowerLimit": "66.2", "upperLimit": "70.5"}, {"groupId": "OG001", "value": "64.8", "lowerLimit": "61.8", "upperLimit": "67.8"}]}]}, {"title": "Week 32", "categories": [{"measurements": [{"groupId": "OG000", "value": "68.1", "lowerLimit": "65.8", "upperLimit": "70.5"}, {"groupId": "OG001", "value": "63.7", "lowerLimit": "60.6", "upperLimit": "66.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire (ACQ) Overall Score at Weeks 16 and 32", "description": "Asthma symptoms were evaluated by the Asthma Control Questionnaire (ACQ). The ACQ has six questions to be answered by the patient, each with a 7 point scale (0-good control, 6-poor control), and one question where the actual pre-bronchodilator FEV1 value expressed in % of predicted FEV1 was classified to scores from 0 (\\> 95% of predicted) to 6 (\\< 50% of predicted). The overall score is the average of the 7 questions; a minimum overall score of 0 = good control of asthma whereas a maximum overall score of 6 = poor control of asthma. A negative change in score indicates improvement in symptoms.", "populationDescription": "mITT with N counts as noted in the category description. To be included in this table patients must have a ACQ measurement for the specified timepoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 16, Week 32", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "Week 16 (N=249,104)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.78", "lowerLimit": "-0.92", "upperLimit": "-0.63"}, {"groupId": "OG001", "value": "-0.11", "lowerLimit": "-0.31", "upperLimit": "0.10"}]}]}, {"title": "Week 32 (N=238,104)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.91", "lowerLimit": "-1.07", "upperLimit": "-0.76"}, {"groupId": "OG001", "value": "-0.04", "lowerLimit": "-0.26", "upperLimit": "0.17"}]}]}, {"title": "Last post-baseline (N=255,119)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.84", "lowerLimit": "-1.00", "upperLimit": "-0.69"}, {"groupId": "OG001", "value": "0.07", "lowerLimit": "-0.14", "upperLimit": "0.27"}]}]}]}, {"type": "SECONDARY", "title": "Number Participants With Clinically Significant Asthma Exacerbations by Category During the 32 Week Treatment Period", "description": "A clinically significant exacerbation episode was defined as a worsening of asthma requiring treatment with rescue systemic (oral or IV) corticosteroids. The initiation of the rescue systemic corticosteroids marked the start of a clinically significant asthma exacerbation episode and cessation of the rescue systemic corticosteroids regimen marked the end of a clinically significant exacerbation episode. If an exacerbation episode was duplicated, overlapped by at least one day with another episode, or nested within another exacerbation episode, only one exacerbation was counted.", "populationDescription": "mITT", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "32 Weeks", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "0 asthma exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "183"}, {"groupId": "OG001", "value": "64"}]}]}, {"title": "1 asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "35"}]}]}, {"title": "2 asthma exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "17"}]}]}, {"title": "3 asthma exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": ">= 4 asthma exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "SECONDARY", "title": "Medical Resource Utilization: Number of Participants With Combined Hospital Admissions, Emergency Room Visits, and Other Outpatient Clinical Visits Due to an Asthma Exacerbation During the 32 Week Treatment Period", "description": "A combined total of unscheduled visits due to asthma exacerbations was calculated for each patient as the total number of hospital admissions, ER visits and unscheduled outpatient clinical visits due to asthma exacerbation. Where more than one type of visit was required on a single day for an asthma exacerbation only the most serious type was included. Where there was more than one visit for a single asthma exacerbation but the visits occurred on different dates, then all were counted.", "populationDescription": "Modified Intent-to-Treat (mITT)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "32 Weeks", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "0 combined visits/hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "226"}, {"groupId": "OG001", "value": "86"}]}]}, {"title": "1 combined visit/hospitalization", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "12"}]}]}, {"title": "2 combined visits/hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "17"}]}]}, {"title": "3 combined visits/hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": ">= 4 combined visits/hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Total number of combined visits/hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "100"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change in Dose of Maintenance Systemic Steroids at Weeks 16 and 32", "description": "For the subgroup of patients requiring maintenance oral (systemic) corticosteroids throughout the screening period the dose of oral steroid (expressed as prednisolone equivalent dose) at baseline, Week 16 and Week 32 was presented by treatment group, as well as the absolute and percent change from baseline to Weeks 16 and 32. It should be noted that the dose of oral steroid at Weeks 16 and 32 was the dose the patient was maintained on and not the dose to treat an exacerbation if one occurred at that time.", "populationDescription": "mITT patients with systemic steriods at baseline (defined as those patient who used systemic steroids throughout the entire run-in period from Visit 1 to Visit 6). N counts as noted in the category description.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Weeks 16 and 32", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"title": "Week 16 (N=56,19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.1", "spread": "63.08"}, {"groupId": "OG001", "value": "36.8", "spread": "212.03"}]}]}, {"title": "Week 32 (N=59,23)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-45.0", "spread": "50.22"}, {"groupId": "OG001", "value": "18.3", "spread": "85.13"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants by Type of Dose Change of Maintenance Systemic Steroids at Weeks 16 and 32", "description": "The type of change for the dose of maintenance systemic steroids could be presented as removal (no more maintenance systemic steroids used), decreased, or maintained.", "populationDescription": "mITT patients with systemic steroids at baseline (defined as those patient who used systemic steroids throughout the entire run-in period from Visit 1 to Visit 6).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Weeks 16 and 32", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"title": "Week 16 - Removed systemic steroids (N=56,19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Week 16 - Decreased systemic steroids (N=56,19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Week 16 - Maintained systemic steroids (N=56,19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "Week 32 - Removed systemic steroids", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Week 32 - Decreased systemic steroids", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Week 32 - Maintained systemic steroids", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "16"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Overall Score by Visit", "description": "There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental exposure). Each question was answered on a 7 point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). The overall AQLQ score is the mean of all 32 responses, and the individual domain scores are the means of the items in those domains (a minimum domain / overall score of 1 = Severely impaired whereas a maximum domain / overall score of 7 = not impaired at all). A positive change from baseline score indicates improvement.", "populationDescription": "mITT at Week 15 for OAT + Omalizumab is 214 patients and for OAT is 92 patients; at Week 31 for OAT + Omalizumab is 224 patients and for OAT is 97 patients except as noted in the category description. To be included in this table patients must have a AQLQ measurement for the specified timepoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 15, Week 31", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "Overall Score: Week 15", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.90", "lowerLimit": "0.73", "upperLimit": "1.07"}, {"groupId": "OG001", "value": "0.03", "lowerLimit": "-0.20", "upperLimit": "0.27"}]}]}, {"title": "Overall Score: Week 31", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.06", "lowerLimit": "0.88", "upperLimit": "1.24"}, {"groupId": "OG001", "value": "-0.07", "lowerLimit": "-0.31", "upperLimit": "0.17"}]}]}, {"title": "Symptom Score: Week 15", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.89", "lowerLimit": "0.70", "upperLimit": "1.09"}, {"groupId": "OG001", "value": "-0.05", "lowerLimit": "-0.31", "upperLimit": "0.22"}]}]}, {"title": "Symptom Score: Week 31", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.07", "lowerLimit": "0.88", "upperLimit": "1.27"}, {"groupId": "OG001", "value": "-0.07", "lowerLimit": "-0.34", "upperLimit": "0.19"}]}]}, {"title": "Activities Score: Week 15", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.87", "lowerLimit": "0.70", "upperLimit": "1.04"}, {"groupId": "OG001", "value": "0.03", "lowerLimit": "-0.20", "upperLimit": "0.26"}]}]}, {"title": "Activities Score: Week 31", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.08", "lowerLimit": "0.91", "upperLimit": "1.26"}, {"groupId": "OG001", "value": "-0.07", "lowerLimit": "-0.31", "upperLimit": "0.17"}]}]}, {"title": "Emotions Score: Week 15", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.98", "lowerLimit": "0.78", "upperLimit": "1.18"}, {"groupId": "OG001", "value": "0.20", "lowerLimit": "-0.07", "upperLimit": "0.48"}]}]}, {"title": "Emotions Score: Week 31", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.08", "lowerLimit": "0.88", "upperLimit": "1.28"}, {"groupId": "OG001", "value": "-0.07", "lowerLimit": "-0.34", "upperLimit": "0.19"}]}]}, {"title": "Enironmental Exposure Score: Week 15 (N=213,91)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.84", "lowerLimit": "0.66", "upperLimit": "1.02"}, {"groupId": "OG001", "value": "0.10", "lowerLimit": "-0.15", "upperLimit": "0.34"}]}]}, {"title": "Enironmental Exposure Score: Week 31(N=223,96)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.91", "lowerLimit": "0.71", "upperLimit": "1.11"}, {"groupId": "OG001", "value": "-0.01", "lowerLimit": "-0.29", "upperLimit": "0.26"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) Index Score and Health State Assessment on Scale From 0 to 100 at Weeks 15 and 31", "description": "The utility-based EQ-5D questionnaire is in two parts and provides a generic measure of health for clinical and economic appraisal. The first \"health state classification\" part has 5 questions each with 3 categories (no problem, moderate problem, severe problems). The second \"visual analogue scale\" was measured from 0 (worst imaginable health state) to 100 (best imaginable health state).", "populationDescription": "Modified Intent-to-Treat with N count as noted in category description.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 15, Week 31", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "EQ-5D Utility Index Score: Week 15 (N=212,90)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.071", "lowerLimit": "0.038", "upperLimit": "0.105"}, {"groupId": "OG001", "value": "0.002", "lowerLimit": "-0.044", "upperLimit": "0.049"}]}]}, {"title": "EQ-5D Utility Index Score: Week 31 (N=194,81)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.091", "lowerLimit": "0.051", "upperLimit": "0.132"}, {"groupId": "OG001", "value": "0.064", "lowerLimit": "0.008", "upperLimit": "0.121"}]}]}, {"title": "Health State Assessment: Week 15 (N=211,89)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.2", "lowerLimit": "4.7", "upperLimit": "11.8"}, {"groupId": "OG001", "value": "-0.4", "lowerLimit": "-5.4", "upperLimit": "4.6"}]}]}, {"title": "Health State Assessment: Week 31 (N=194,80)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.3", "lowerLimit": "5.2", "upperLimit": "13.4"}, {"groupId": "OG001", "value": "-2.8", "lowerLimit": "-8.5", "upperLimit": "3.0"}]}]}]}, {"type": "SECONDARY", "title": "Changes From Baseline to Week 31 in the Percent Overall Work Impairment Due to Asthma Problems", "description": "The Work Productivity and Activity Impairment-Allergic Asthma (WPAI-AA) questionnaire measures time missed from work, impairment of work and regular activities within the last 7 days. Questionnaires were administered via phone 1 week prior to the study visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Overall work impairment due to asthma problems is derived from the proportion of hours missed from work due to asthma and the degree to which asthma problems affected productivity while working.", "populationDescription": "Modified Intent-to-Treat. Only patients only who worked and with values at both baseline and Week 31 visit were included. Sensitivity analysis excluded questionnaires which were answered after the clinic visit.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent impairment", "timeFrame": "Baseline and Week 31", "groups": [{"id": "OG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level."}, {"id": "OG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.3", "spread": "26.19"}, {"groupId": "OG001", "value": "39.4", "spread": "24.91"}]}]}, {"title": "Week 31", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.5", "spread": "24.28"}, {"groupId": "OG001", "value": "40.3", "spread": "27.97"}]}]}, {"title": "Change from baseline at Week 31", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.8", "spread": "26.38"}, {"groupId": "OG001", "value": "0.8", "spread": "30.34"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "OAT + Omalizumab", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level.", "seriousNumAffected": 29, "seriousNumAtRisk": 274, "otherNumAffected": 140, "otherNumAtRisk": 274}, {"id": "EG001", "title": "Optimized Asthma Treatment (OAT)", "description": "During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for an additional 32 weeks.", "seriousNumAffected": 17, "seriousNumAtRisk": 128, "otherNumAffected": 65, "otherNumAtRisk": 128}], "seriousEvents": [{"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Hyperparathyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Melaena", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Polyp", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 128}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Orchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Chest injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Facial bones fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Fractured coccyx", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Foot deformity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Breast neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Fibroadenoma of breast", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Intra-uterine death", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 128}]}, {"term": "Pleuritic pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 128}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 128}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 128}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 38, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 128}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 128}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 128}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 128}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 82, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 51, "numAtRisk": 128}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 128}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 274}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}